Bristol-Myers Squibb Company (BMY) $57.58
Bristol-Myers Squibb is flashing a rare, near-perfect technical confluence score of 90/100, yet chasing this rally today could leave you holding the bag.
52-wk High $62.89
📌 Investment Snapshot
- Valuation sits at an attractive 16.1x P/E with a robust 4.38% dividend yield protecting the downside.
- Latest Q1 2026 earnings delivered revenue of $11.49B and EPS of $1.31, showing stable operational execution.
- A powerful 90/100 Technical Confluence Score confirms strong institutional accumulation over the past quarter.
- Consensus mean target of $63.00 implies a modest 9.4% upside, suggesting limited immediate margin of safety.
BMY is exhibiting strong structural health, supported by a rising 50-day moving average and solid institutional backing. However, the stock is currently trading directly into short-term resistance with an overextended momentum profile.
| 📍 Entry Zone | $55.56 to $56.50 | 🛑 Stop-Loss | $52.90 |
| 📋 Adjust If | the 50-day moving average ($56.29) fails to hold on high volume. | ||
The Investment Case — Why Now?
Over the last 90 days, Bristol-Myers Squibb has quietly engineered a structural turnaround, climbing over 4.7% in the past month alone. This price action reflects growing institutional confidence as the company navigates its upcoming patent cliff with newly launched portfolio assets. Capital is clearly rotating back into high-yielding defensive healthcare names as macro uncertainty lingers.
The primary risk remains the transition of key blockbusters like Eliquis and Revlimid to generic competition, which continues to squeeze legacy margins. While the current 4.38% dividend yield provides a highly attractive cushion, dividend coverage will tighten if newly launched drugs fail to scale rapidly. We must see sustained high-volume breakout confirmation before committing fresh capital at these elevated levels.
🤔 Can BMY’s new drug pipeline scale fast enough to offset the impending $10B patent cliff of its legacy blockbusters?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – General |
| Dividend Yield | 4.38% |
| Free Cash Flow (Q1) | $0.8B |
📈 Price Action & Technicals
Golden Cross
Inside VA
Sell-side Sweep at $58.22 on 2026-07-07
BMY is currently trading above both its 50-day SMA ($56.29) and 200-day SMA ($53.16), confirming a medium-term bullish regime shift. The price is tightly hugging the upper Bollinger Band ($59.10), which typically acts as a short-term ceiling during low-volatility regimes.
The RSI of 65.1 signals that momentum is running hot, though the positive MACD histogram crossover (+0.47 vs 0.20 signal) confirms that buyers remain in control. The ADX at 20.0 indicates a developing trend, but the wide spread between +DI (29.7) and -DI (7.3) warns of a temporary overextension.
Our Volume Profile analysis shows the Point of Control (POC) sits at $57.06, directly beneath the current price. This high-volume node should act as immediate structural support during any minor pullbacks.
Recent liquidity sweeps reveal institutional distribution near the highs, highlighted by a sell-side sweep at $58.22 on July 7. This suggests smart money is taking profits near the top of the current trading range.
Historically, when BMY reaches these technical parameters with an open bullish Fair Value Gap (FVG) below ($55.56~$56.53), the price tends to mean-revert to fill the gap before resuming its upward trajectory.
🤔 With the RSI hovering near 65, are you willing to buy BMY here, or will you wait for the FVG gap fill at $56.50?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| BMY | Bristol-Myers Squibb | 16.1x |
| PFE | Pfizer Inc. | 14.5x |
| MRK | Merck & Co. | 18.2x |
| LLY | Eli Lilly & Co. | 55.4x |
| SPY | S&P 500 Average | 22.1x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $11.49B | $1.31 | -2.1% |
| Q4 2025 | $12.50B | $0.54 | +1.2% |
| Q3 2025 | $12.22B | $1.08 | -0.8% |
| Q2 2025 | $12.27B | $0.64 | +0.5% |
Free Cash Flow for the latest quarter came in at a stable $0.8B, supporting the company’s commitment to its dividend program.
Bristol-Myers Squibb has demonstrated highly consistent revenue generation, hovering between $11.4B and $12.5B over the past four quarters. While top-line growth remains flat due to generic erosion, disciplined cost management has allowed EPS to rebound significantly to $1.31 in the most recent quarter.
🚀 Growth Drivers — What Moves the Stock
- New Product Portfolio Expansion 🟢 Upside Surprise — Rapid adoption of Reblozyl and Opdualag is offseting legacy declines, with new launch sales growing double-digits.
- Milvexian Phase 3 Trials 🟢 Upside Surprise — The novel oral anticoagulant Milvexian represents a multi-billion dollar opportunity to replace Eliquis.
- Revlimid Generic Erosion 🟡 Priced In — The ongoing volume decline of Revlimid is well-documented and largely factored into current conservative valuations.
🤔 Does BMY’s pipeline possess enough blockbuster potential to completely replace the revenue of Eliquis by 2028?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 171,682 |
| Vanguard Capital Management LLC | 132,320 |
| State Street Corporation | 98,564 |
| JPMORGAN CHASE & CO | 92,475 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| HALLER JULIA A | Director | 2026-06-15 | Purchase | 20,460 |
| SHORT BARTIE WENDY | Officer | 2026-06-03 | Purchase | 8,040 |
| ELKINS DAVID VINCENT | Chief Financial Officer | 2026-04-01 | Purchase | 30,000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.0% | 2.9 |
⚠ Key Risk Factors
~$15B impact
~$2B impact
🎯 Guidance & Wall Street View
Management continues to target mid-single-digit revenue growth for its new product portfolio through 2030.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $75.00 | $63.00 | $40.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| B of A Securities | Buy | $63.00 | 2026-07-10 | Maintained |
| Cantor Fitzgerald | Neutral | $58.00 | 2026-07-06 | Reiterated |
| Guggenheim | Buy | $68.00 | 2026-04-08 | Reiterated |
Wall Street remains cautiously optimistic on BMY. While B of A Securities maintains a Buy rating, Cantor Fitzgerald’s Neutral stance reflects the consensus view that near-term upside is capped near $63.00.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- New oncology and immunology launches exceed consensus estimates by 15%.
- Milvexian clinical data shows superior efficacy, securing a massive market share.
📊 Base Case
BMY successfully transitions its portfolio with moderate growth from new launches, maintaining its dividend easily.
🐻 Bear Case
- Generic erosion of Revlimid accelerates faster than the new portfolio can scale.
- Regulatory headwinds from the IRA severely damage long-term margin profiles.
🎯 Investor Action Plan — By Profile
Do not chase the current rally. Wait for a pullback into the open bullish FVG zone between $55.56 and $56.53, which aligns with the 50-day SMA support.
Existing positions should be held to collect the secure 4.38% dividend. Avoid adding fresh capital until the stock successfully reclaims and consolidates above $58.50.
Patience is key. While the 16.1x P/E is historically cheap, wait for broader pipeline clarity or a market-wide correction to buy closer to the $53.00 long-term VWAP anchor.
❓ Investor FAQ — People Also Ask
Q: Is Bristol-Myers Squibb’s 4.38% dividend safe?
Yes, backed by $0.8B in quarterly free cash flow and a stable payout ratio, the dividend remains highly secure for the foreseeable future.
Q: What is the key technical level to watch for BMY?
The critical level is the $55.56 to $56.53 bullish Fair Value Gap (FVG), which represents the ideal institutional entry zone.
Q: How does BMY compare to its peers on valuation?
At 16.1x P/E, BMY trades at a discount to the S&P 500 average of 22.1x and peer Merck (18.2x), offering solid defensive value.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#BMY #BristolMyersSquibb #Healthcare #Dividends #ValueInvesting #TechnicalAnalysis